glipizide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 1301 29094-61-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • glypidizine
  • glidiazinamide
  • K 4024
  • K-4024
  • K4024
  • glipizide
  • dipazide
  • glibenese
  • glipizid
  • glucotrol
  • glucozide
  • glupizide
  • glydiazinamide
  • melizide
  • napizide
  • sucrazide
An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
  • Molecular weight: 445.54
  • Formula: C21H27N5O4S
  • CLOGP: 2.60
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 130.15
  • ALOGS: -4.43
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.96 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.56 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.30 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 8, 1984 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 683.95 12.09 482 35613 83274 63369653
Hypoglycaemia 417.90 12.09 314 35781 59751 63393176
Cardiac failure congestive 326.25 12.09 328 35767 92105 63360822
Blood glucose decreased 288.85 12.09 168 35927 20784 63432143
Coronary artery disease 198.21 12.09 157 35938 32220 63420707
Myocardial infarction 197.50 12.09 263 35832 99630 63353297
Diabetes mellitus inadequate control 151.61 12.09 99 35996 15027 63437900
Product residue present 129.23 12.09 57 36038 3922 63449005
Cerebrovascular accident 122.48 12.09 220 35875 107804 63345123
Contraindicated product administered 109.78 12.09 3 36092 217645 63235282
Glycosylated haemoglobin increased 109.46 12.09 75 36020 12323 63440604
Blood glucose fluctuation 85.90 12.09 45 36050 4531 63448396
Pancreatitis 84.58 12.09 121 35974 48934 63403993
Drug intolerance 79.61 12.09 38 36057 308623 63144304
Infusion related reaction 79.00 12.09 21 36074 245500 63207427
Synovitis 72.76 12.09 10 36085 186908 63266019
Off label use 72.58 12.09 174 35921 674288 62778639
Rheumatoid arthritis 72.24 12.09 27 36068 253792 63199135
Systemic lupus erythematosus 70.85 12.09 16 36079 208902 63244025
Exposure during pregnancy 69.17 12.09 5 36090 155542 63297385
Glossodynia 68.62 12.09 10 36085 178866 63274061
Lactic acidosis 68.30 12.09 96 35999 38191 63414736
Product complaint 67.60 12.09 57 36038 12752 63440175
Drug ineffective 63.52 12.09 343 35752 1044422 62408505
Treatment failure 62.19 12.09 18 36077 199025 63253902
Hyperglycaemia 61.75 12.09 96 35999 41771 63411156
Pericarditis 59.16 12.09 4 36091 131575 63321352
Hypoglycaemic coma 59.07 12.09 29 36066 2546 63450381
Renal failure 56.55 12.09 171 35924 117481 63335446
Arthropathy 53.12 12.09 34 36061 234758 63218169
Blood glucose abnormal 52.01 12.09 40 36055 7852 63445075
Joint swelling 52.00 12.09 66 36029 327600 63125327
Lower respiratory tract infection 51.66 12.09 7 36088 132300 63320627
Mental status changes 50.50 12.09 85 36010 39514 63413413
Diabetes mellitus 50.08 12.09 103 35992 55707 63397220
Product use issue 49.80 12.09 32 36063 220488 63232439
Euglycaemic diabetic ketoacidosis 49.39 12.09 29 36066 3645 63449282
General physical health deterioration 48.60 12.09 27 36068 201375 63251552
Wound 45.37 12.09 18 36077 163245 63289682
Discomfort 44.04 12.09 20 36075 167354 63285573
Ischaemic cardiomyopathy 42.66 12.09 23 36072 2454 63450473
Diabetic ketoacidosis 42.01 12.09 55 36040 20450 63432477
Dehydration 41.67 12.09 202 35893 173152 63279775
Product dose omission issue 41.42 12.09 251 35844 234062 63218865
Musculoskeletal stiffness 40.04 12.09 28 36067 184590 63268337
C-reactive protein increased 39.48 12.09 4 36091 94703 63358224
Acute kidney injury 39.10 12.09 270 35825 263145 63189782
Helicobacter infection 38.47 12.09 4 36091 92781 63360146
Chest pain 37.94 12.09 231 35864 215728 63237199
Pyrexia 35.78 12.09 142 35953 470336 62982591
Acute myocardial infarction 34.55 12.09 64 36031 32060 63420867
Cutaneous T-cell dyscrasia 34.47 12.09 8 36087 62 63452865
Alopecia 33.90 12.09 90 36005 337446 63115481
Asthenia 33.89 12.09 350 35745 383254 63069673
Oedema peripheral 33.46 12.09 203 35892 189308 63263619
Thrombosis 32.88 12.09 96 35999 64659 63388268
Swelling 32.81 12.09 67 36028 275311 63177616
Myocardial ischaemia 31.96 12.09 38 36057 12821 63440106
Urinary tract infection 30.66 12.09 256 35839 264428 63188499
Nodular rash 30.24 12.09 9 36086 196 63452731
Hepatic enzyme increased 29.79 12.09 43 36052 202285 63250642
Transient ischaemic attack 29.63 12.09 66 36029 37687 63415240
Cardiac disorder 28.39 12.09 78 36017 50738 63402189
Diabetic neuropathy 28.13 12.09 21 36074 3943 63448984
Gout 27.81 12.09 36 36059 13235 63439692
Chronic kidney disease 27.71 12.09 72 36023 45326 63407601
Product appearance confusion 26.77 12.09 6 36089 39 63452888
Weight decreased 26.56 12.09 257 35838 276541 63176386
Chronic obstructive pulmonary disease 26.32 12.09 87 36008 62599 63390328
Arthralgia 24.87 12.09 206 35889 569504 62883423
Stool analysis abnormal 24.86 12.09 6 36089 56 63452871
Therapeutic product effect decreased 24.74 12.09 45 36050 193142 63259785
Product use in unapproved indication 24.50 12.09 40 36055 179040 63273887
Condition aggravated 24.27 12.09 132 35963 402085 63050842
Ventricular hypertrophy 23.93 12.09 18 36077 3418 63449509
Renal injury 23.63 12.09 28 36067 9411 63443516
Hypoacusis 23.36 12.09 46 36049 24105 63428822
Pancreatitis acute 23.03 12.09 49 36046 27117 63425810
Pernicious anaemia 23.00 12.09 10 36085 664 63452263
Drug abuse 21.83 12.09 7 36088 72511 63380416
Coronary artery occlusion 21.68 12.09 25 36070 8166 63444761
Cardiovascular disorder 21.63 12.09 30 36065 11782 63441145
Diarrhoea 21.49 12.09 545 35550 714821 62738106
Nausea 21.46 12.09 636 35459 853835 62599092
Irritable bowel syndrome 21.43 12.09 10 36085 82402 63370525
Knee arthroplasty 20.84 12.09 3 36092 54203 63398724
Acute coronary syndrome 20.49 12.09 27 36068 10099 63442828
Suicide attempt 19.97 12.09 5 36090 60913 63392014
Dizziness 19.17 12.09 347 35748 429578 63023349
Death 19.16 12.09 309 35786 374072 63078855
Treatment noncompliance 18.62 12.09 55 36040 37270 63415657
Injection site nodule 18.07 12.09 16 36079 3819 63449108
Liver injury 17.94 12.09 6 36089 60514 63392413
Ventricular dysfunction 17.91 12.09 14 36081 2814 63450113
Dilatation atrial 17.47 12.09 12 36083 1979 63450948
Haemorrhage intracranial 17.36 12.09 29 36066 13390 63439537
Product quality issue 17.09 12.09 52 36043 35813 63417114
Plasma cell myeloma 17.05 12.09 52 36043 35853 63417074
Hyperinsulinaemia 16.88 12.09 5 36090 107 63452820
Rhabdomyolysis 16.70 12.09 59 36036 43892 63409035
Cellulitis 16.54 12.09 91 36004 81867 63371060
Abdominal discomfort 16.35 12.09 111 35984 320774 63132153
Hyperlipidaemia 16.25 12.09 35 36060 19536 63433391
Angina unstable 16.06 12.09 20 36075 7075 63445852
Adenocarcinoma pancreas 15.80 12.09 9 36086 1069 63451858
Blood potassium increased 15.49 12.09 33 36062 18276 63434651
Hip arthroplasty 15.44 12.09 4 36091 47642 63405285
Emotional distress 15.33 12.09 47 36048 32502 63420425
Haemodialysis 15.31 12.09 22 36073 8925 63444002
Pancreatitis haemorrhagic 15.28 12.09 7 36088 526 63452401
Abortion spontaneous 15.23 12.09 4 36091 47191 63405736
Hypersensitivity 15.03 12.09 101 35994 292584 63160343
Acute respiratory failure 14.60 12.09 48 36047 34437 63418490
Intentional product use issue 14.47 12.09 32 36063 127860 63325067
Hypervolaemia 14.30 12.09 42 36053 28371 63424556
Fear 14.02 12.09 29 36066 15737 63437190
Leukopenia 13.94 12.09 14 36081 77276 63375651
Peripheral vascular disorder 13.64 12.09 17 36078 6018 63446909
Blood triglycerides increased 13.58 12.09 25 36070 12463 63440464
Arteriosclerosis coronary artery 13.47 12.09 20 36075 8353 63444574
Coronary artery stenosis 13.44 12.09 15 36080 4729 63448198
Pancreatic carcinoma 13.41 12.09 19 36076 7609 63445318
Infection 13.37 12.09 76 36019 229097 63223830
International normalised ratio increased 13.29 12.09 57 36038 46368 63406559
Glucose urine present 13.18 12.09 7 36088 725 63452202
Unevaluable event 13.14 12.09 61 36034 51325 63401602
Gastrointestinal haemorrhage 13.09 12.09 85 36010 81091 63371836
Angioedema 13.05 12.09 58 36037 47907 63405020
Loss of personal independence in daily activities 13.04 12.09 22 36073 97268 63355659
Blood pressure fluctuation 13.03 12.09 5 36090 46312 63406615
Cardiomegaly 12.94 12.09 30 36065 17584 63435343
Completed suicide 12.86 12.09 133 35962 145540 63307387
Therapeutic product effect incomplete 12.79 12.09 33 36062 125023 63327904
Psoriasis 12.79 12.09 89 36006 86868 63366059
Essential hypertension 12.72 12.09 15 36080 5018 63447909
Blister 12.71 12.09 35 36060 129779 63323148
Flatulence 12.68 12.09 46 36049 34656 63418271
Hypoglycaemic seizure 12.68 12.09 6 36089 486 63452441
Fluid retention 12.53 12.09 67 36028 59619 63393308
Fall 12.35 12.09 301 35794 392033 63060894
Pregnancy 12.12 12.09 3 36092 36833 63416094

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 674.42 12.16 520 37152 54120 34865139
Blood glucose increased 528.47 12.16 492 37180 66226 34853033
Cardiac failure congestive 305.54 12.16 411 37261 82859 34836400
Myocardial infarction 270.79 12.16 475 37197 120610 34798649
Coronary artery disease 193.29 12.16 249 37423 48056 34871203
Blood glucose decreased 182.87 12.16 135 37537 13102 34906157
Completed suicide 141.71 12.16 321 37351 97847 34821412
Off label use 119.88 12.16 167 37505 419357 34499902
Glycosylated haemoglobin increased 92.02 12.16 85 37587 11275 34907984
Cerebrovascular accident 91.28 12.16 248 37424 84563 34834696
Drug abuse 83.65 12.16 6 37666 99090 34820169
Pancreatitis 64.94 12.16 135 37537 38756 34880503
Product complaint 61.65 12.16 51 37621 5839 34913420
Blood glucose abnormal 59.11 12.16 50 37622 5902 34913357
Diabetes mellitus inadequate control 54.71 12.16 70 37602 13394 34905865
General physical health deterioration 50.01 12.16 39 37633 128230 34791029
Product residue present 49.55 12.16 33 37639 2713 34916546
Product use in unapproved indication 49.37 12.16 33 37639 117466 34801793
Myocardial ischaemia 47.73 12.16 75 37597 17333 34901926
Injury 47.14 12.16 82 37590 20605 34898654
Mental status changes 45.64 12.16 116 37556 37967 34881292
Febrile neutropenia 43.52 12.16 50 37622 136799 34782460
Cardiovascular disorder 40.41 12.16 52 37620 10004 34909255
Cardiac disorder 40.38 12.16 120 37552 43006 34876253
Ischaemic cardiomyopathy 39.05 12.16 41 37631 6348 34912911
C-reactive protein increased 38.69 12.16 6 37666 54092 34865167
Diabetic neuropathy 37.12 12.16 33 37639 4164 34915095
Myasthenic syndrome 34.57 12.16 15 37657 516 34918743
Blood glucose fluctuation 32.24 12.16 30 37642 4014 34915245
Interstitial lung disease 32.21 12.16 15 37657 65267 34853992
Neutropenia 31.56 12.16 77 37595 156701 34762558
Spur cell anaemia 29.85 12.16 8 37664 58 34919201
Emotional distress 27.25 12.16 54 37618 14972 34904287
Autoimmune myocarditis 27.01 12.16 10 37662 225 34919034
Pyrexia 26.77 12.16 230 37442 332783 34586476
Hypophagia 26.55 12.16 71 37601 23951 34895308
Drug ineffective 26.37 12.16 341 37331 456410 34462849
Diabetic ketoacidosis 25.98 12.16 59 37613 17973 34901286
Pancreatitis acute 25.10 12.16 77 37595 28064 34891195
Arteriosclerosis 24.14 12.16 45 37627 11923 34907336
Asthenia 23.94 12.16 384 37288 244867 34674392
Acute myocardial infarction 23.26 12.16 117 37555 53602 34865657
Transient ischaemic attack 23.20 12.16 74 37598 27539 34891720
Angina unstable 22.50 12.16 43 37629 11610 34907649
Diabetes mellitus 21.66 12.16 104 37568 46769 34872490
Product dose omission issue 20.93 12.16 209 37463 119502 34799757
Unresponsive to stimuli 20.59 12.16 71 37601 27498 34891761
Anhedonia 19.85 12.16 32 37640 7553 34911706
Type 2 diabetes mellitus 19.37 12.16 49 37623 15983 34903276
Arteriosclerosis coronary artery 19.28 12.16 42 37630 12443 34906816
Intentional product use issue 18.84 12.16 22 37650 59794 34859465
Renal injury 18.83 12.16 39 37633 11156 34908103
Drug resistance 18.26 12.16 3 37669 25924 34893335
Interstitial granulomatous dermatitis 18.22 12.16 7 37665 175 34919084
Cardiomyopathy 17.89 12.16 49 37623 16759 34902500
Bladder cancer 17.87 12.16 48 37624 16230 34903029
Gastrointestinal mucosal necrosis 17.86 12.16 7 37665 185 34919074
Leukopenia 17.84 12.16 25 37647 62831 34856428
Acute kidney injury 16.90 12.16 439 37233 304549 34614710
Agranulocytosis 16.24 12.16 3 37669 23818 34895441
Autoimmune myositis 16.17 12.16 6 37666 136 34919123
Glycosylated haemoglobin decreased 16.05 12.16 8 37664 379 34918880
Treatment failure 16.01 12.16 16 37656 46681 34872578
Diverticulum 15.81 12.16 28 37644 7131 34912128
Condition aggravated 15.73 12.16 132 37540 192064 34727195
Product quality issue 15.55 12.16 47 37625 16988 34902271
Altered state of consciousness 15.36 12.16 3 37669 22890 34896369
Renal failure 15.27 12.16 211 37461 130346 34788913
Product use issue 15.25 12.16 28 37644 63188 34856071
Pancreatic carcinoma 14.96 12.16 31 37641 8870 34910389
Poor quality product administered 14.92 12.16 14 37658 1893 34917366
Glycosylated haemoglobin abnormal 14.72 12.16 6 37666 176 34919083
Drug intolerance 14.72 12.16 26 37646 59544 34859715
Mucosal inflammation 14.71 12.16 12 37660 38610 34880649
Alanine aminotransferase increased 14.49 12.16 42 37630 80773 34838486
Chest pain 14.47 12.16 204 37468 126558 34792701
Peripheral vascular disorder 14.22 12.16 22 37650 5014 34914245
COVID-19 14.13 12.16 40 37632 77510 34841749
Weight decreased 13.92 12.16 267 37405 176034 34743225
Suicide attempt 13.87 12.16 13 37659 39103 34880156
Neutrophil count decreased 13.84 12.16 21 37651 51083 34868176
Blood pressure fluctuation 13.75 12.16 5 37667 25244 34894015
Hyperglycaemia 13.72 12.16 81 37591 39399 34879860
Electrocardiogram ST-T change 13.16 12.16 8 37664 561 34918698
Lower respiratory tract infection 13.12 12.16 9 37663 31628 34887631
Hyphaema 12.93 12.16 8 37664 579 34918680
Cytomegalovirus infection 12.89 12.16 6 37666 26129 34893130
Coronary artery occlusion 12.72 12.16 33 37639 10929 34908330
International normalised ratio increased 12.71 12.16 91 37581 47236 34872023
Vision blurred 12.71 12.16 89 37583 45874 34873385
Fear 12.64 12.16 32 37640 10444 34908815
Expiratory reserve volume decreased 12.63 12.16 4 37668 55 34919204
Infusion related reaction 12.36 12.16 24 37648 53033 34866226

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 1081.43 11.54 752 56338 100842 79586456
Blood glucose increased 824.40 11.54 672 56418 114303 79572995
Cardiac failure congestive 525.36 11.54 576 56514 141826 79545472
Myocardial infarction 476.97 11.54 622 56468 183507 79503791
Blood glucose decreased 360.36 11.54 228 56862 26006 79661292
Coronary artery disease 340.28 11.54 319 56771 65155 79622143
Cerebrovascular accident 205.06 11.54 385 56705 154907 79532391
Completed suicide 174.47 11.54 476 56614 245291 79442007
Off label use 157.46 11.54 255 56835 906960 78780338
Glycosylated haemoglobin increased 149.21 11.54 118 56972 19142 79668156
Product residue present 126.19 11.54 58 57032 3478 79683820
Diabetes mellitus inadequate control 112.32 11.54 111 56979 24153 79663145
Pancreatitis 97.94 11.54 176 56914 68399 79618899
Drug ineffective 92.82 11.54 429 56661 1080484 78606814
Mental status changes 92.01 11.54 169 56921 66790 79620508
Drug intolerance 91.93 11.54 37 57053 264082 79423216
Contraindicated product administered 86.43 11.54 7 57083 157531 79529767
Product complaint 85.02 11.54 73 57017 13276 79674022
Rheumatoid arthritis 83.37 11.54 23 57067 208447 79478851
Drug abuse 82.02 11.54 10 57080 162681 79524617
Ischaemic cardiomyopathy 81.72 11.54 57 57033 7638 79679660
General physical health deterioration 80.05 11.54 49 57041 275189 79412109
Blood glucose abnormal 73.92 11.54 61 57029 10505 79676793
Infusion related reaction 72.70 11.54 37 57053 230200 79457098
Synovitis 71.88 11.54 11 57079 150723 79536575
Myocardial ischaemia 70.24 11.54 89 57001 25430 79661868
Acute myocardial infarction 68.89 11.54 163 56927 76873 79610425
Cardiac disorder 68.69 11.54 148 56942 65609 79621689
Lactic acidosis 68.57 11.54 154 56936 70205 79617093
Blood glucose fluctuation 67.49 11.54 48 57042 6634 79680664
Acute kidney injury 63.29 11.54 608 56482 518796 79168502
C-reactive protein increased 62.48 11.54 9 57081 129018 79558280
Euglycaemic diabetic ketoacidosis 61.93 11.54 46 57044 6798 79680500
Hand deformity 61.81 11.54 3 57087 103916 79583382
Cardiovascular disorder 59.61 11.54 69 57021 17956 79669342
Hyperglycaemia 58.79 11.54 145 56945 70190 79617108
Treatment failure 57.50 11.54 25 57065 170461 79516837
Lower respiratory tract infection 56.06 11.54 12 57078 129208 79558090
Diabetic ketoacidosis 55.80 11.54 93 56997 34029 79653269
Renal failure 54.55 11.54 286 56804 200682 79486616
Product use in unapproved indication 53.70 11.54 60 57030 250299 79436999
Diabetic neuropathy 52.30 11.54 40 57050 6176 79681122
Hypoglycaemic coma 52.29 11.54 36 57054 4724 79682574
Transient ischaemic attack 50.96 11.54 115 56975 52580 79634718
Diabetes mellitus 50.74 11.54 147 56943 78243 79609055
Product dose omission issue 50.73 11.54 327 56763 247210 79440088
Asthenia 49.59 11.54 572 56518 511117 79176181
Pericarditis 48.80 11.54 8 57082 104228 79583070
Pyrexia 48.67 11.54 286 56804 678423 79008875
Arthropathy 46.82 11.54 35 57055 177076 79510222
Product use issue 44.21 11.54 51 57039 209771 79477527
Death 43.69 11.54 607 56483 565907 79121391
Angina unstable 42.90 11.54 56 57034 16471 79670827
Chest pain 42.86 11.54 347 56743 281957 79405341
Systemic lupus erythematosus 42.07 11.54 17 57073 121132 79566166
Musculoskeletal stiffness 40.84 11.54 39 57051 174969 79512329
Hypophagia 40.56 11.54 96 56994 45271 79642027
Joint swelling 38.71 11.54 94 56996 288552 79398746
Chronic obstructive pulmonary disease 38.00 11.54 141 56949 85278 79602020
Dehydration 37.62 11.54 305 56785 247882 79439416
Glossodynia 36.71 11.54 14 57076 103323 79583975
Rhabdomyolysis 35.34 11.54 157 56933 102974 79584324
Pancreatitis acute 34.02 11.54 95 56995 49509 79637789
Coronary artery occlusion 33.85 11.54 48 57042 15267 79672031
Myasthenic syndrome 33.82 11.54 15 57075 827 79686471
Helicobacter infection 33.42 11.54 5 57085 69699 79617599
Treatment noncompliance 32.85 11.54 97 56993 52171 79635127
Product quality issue 32.73 11.54 74 57016 33866 79653432
Cutaneous T-cell dyscrasia 32.63 11.54 8 57082 62 79687236
Arteriosclerosis coronary artery 32.45 11.54 51 57039 17765 79669533
Emotional distress 31.92 11.54 81 57009 39888 79647410
Bladder cancer 31.63 11.54 53 57037 19473 79667825
Renal injury 31.59 11.54 49 57041 16878 79670420
Condition aggravated 31.34 11.54 220 56870 500904 79186394
Arthralgia 31.09 11.54 261 56829 571542 79115756
International normalised ratio increased 30.57 11.54 131 56959 84590 79602708
Febrile neutropenia 30.36 11.54 76 57014 230923 79456375
Arteriosclerosis 30.23 11.54 50 57040 18177 79669121
Hypoacusis 29.37 11.54 66 57024 30084 79657214
Alopecia 28.96 11.54 78 57012 231277 79456021
Spur cell anaemia 28.29 11.54 8 57082 113 79687185
Unresponsive to stimuli 28.16 11.54 96 56994 55692 79631606
Intentional product use issue 27.89 11.54 41 57049 152071 79535227
Drug reaction with eosinophilia and systemic symptoms 27.79 11.54 6 57084 64238 79623060
Peripheral vascular disorder 26.99 11.54 31 57059 7999 79679299
Therapeutic product effect decreased 26.46 11.54 48 57042 163815 79523483
Neutropenia 26.43 11.54 111 56979 287599 79399699
Interstitial lung disease 26.37 11.54 25 57065 112575 79574723
Gamma-glutamyltransferase increased 26.03 11.54 4 57086 54676 79632622
Discomfort 25.95 11.54 31 57059 125586 79561712
Blood pressure fluctuation 25.74 11.54 8 57082 67137 79620161
Infection 25.60 11.54 88 57002 241624 79445674
Gastrointestinal haemorrhage 25.40 11.54 187 56903 147532 79539766
Autoimmune myocarditis 25.37 11.54 10 57080 409 79686889
Oedema peripheral 25.25 11.54 284 56806 252004 79435294
Chronic kidney disease 25.20 11.54 104 56986 66050 79621248
Acute coronary syndrome 24.91 11.54 50 57040 21083 79666215
Wound 24.72 11.54 28 57062 116151 79571147
Irritable bowel syndrome 24.62 11.54 7 57083 62234 79625064
Nodular rash 24.24 11.54 9 57081 312 79686986
Thrombosis 23.70 11.54 121 56969 83979 79603319
Anhedonia 23.55 11.54 40 57050 14858 79672440
Mitral valve incompetence 22.93 11.54 58 57032 28507 79658791
Atrial fibrillation 22.71 11.54 229 56861 197657 79489641
Stool analysis abnormal 22.63 11.54 7 57083 137 79687161
Suicide attempt 22.41 11.54 16 57074 82916 79604382
Occult blood positive 22.18 11.54 26 57064 6857 79680441
Inflammation 21.74 11.54 21 57069 93732 79593566
Angioedema 21.15 11.54 109 56981 75926 79611372
Cellulitis 21.05 11.54 142 56948 108918 79578380
Hyperlipidaemia 20.96 11.54 53 57037 26040 79661258
Injury 20.80 11.54 110 56980 77386 79609912
Cardiomyopathy 20.62 11.54 56 57034 28718 79658580
Drug resistance 20.30 11.54 3 57087 42210 79645088
Fear 20.16 11.54 47 57043 21939 79665359
Agranulocytosis 19.90 11.54 4 57086 45026 79642272
Therapeutic product effect incomplete 19.87 11.54 45 57045 141600 79545698
Gout 19.60 11.54 50 57040 24699 79662599
Gastrointestinal mucosal necrosis 19.41 11.54 7 57083 223 79687075
Dizziness 19.22 11.54 503 56587 525938 79161360
Hyperkalaemia 19.20 11.54 144 56946 114254 79573044
Glycosylated haemoglobin abnormal 19.18 11.54 7 57083 231 79687067
Haemodialysis 19.09 11.54 41 57049 18127 79669171
Interstitial granulomatous dermatitis 19.07 11.54 7 57083 235 79687063
Pernicious anaemia 18.87 11.54 9 57081 587 79686711
Blood creatinine increased 18.54 11.54 181 56909 154876 79532422
Cognitive disorder 18.23 11.54 14 57076 69912 79617386
Plasma cell myeloma 18.18 11.54 81 57009 53178 79634120
Essential hypertension 18.08 11.54 22 57068 6031 79681267
Leukopenia 18.04 11.54 35 57055 116478 79570820
Fibromyalgia 17.93 11.54 12 57078 64328 79622970
Dialysis 17.52 11.54 40 57050 18422 79668876
Poor quality product administered 17.47 11.54 17 57073 3628 79683670
Type 2 diabetes mellitus 17.38 11.54 84 57006 57038 79630260
Dilatation atrial 17.24 11.54 17 57073 3687 79683611
Ventricular hypertrophy 17.22 11.54 23 57067 6915 79680383
Cholestasis 17.00 11.54 8 57082 52101 79635197
Urinary tract infection 16.79 11.54 283 56807 274229 79413069
Weight decreased 16.50 11.54 351 56739 354847 79332451
Cytomegalovirus infection 16.49 11.54 5 57085 42639 79644659
Toe amputation 16.46 11.54 17 57073 3894 79683404
Hyperinsulinaemia 16.35 11.54 6 57084 201 79687097
Blood potassium increased 16.22 11.54 52 57038 29223 79658075
Diabetic retinopathy 15.86 11.54 15 57075 3091 79684207
Altered state of consciousness 15.45 11.54 6 57084 43816 79643482
Gastrointestinal disorder 15.43 11.54 41 57049 122164 79565134
Epilepsy 15.43 11.54 5 57085 40855 79646443
Hyphaema 15.34 11.54 9 57081 895 79686403
Coronary artery stenosis 15.27 11.54 30 57060 12454 79674844
Liver injury 15.19 11.54 11 57079 56603 79630695
Blood loss anaemia 15.18 11.54 34 57056 15464 79671834
Cardiac arrest 15.12 11.54 189 56901 171907 79515391
Hypersensitivity 14.99 11.54 118 56972 262121 79425177
Unevaluable event 14.98 11.54 79 57011 55506 79631792
Vision blurred 14.88 11.54 128 56962 105770 79581528
Product appearance confusion 14.82 11.54 4 57086 47 79687251
Impaired healing 14.76 11.54 25 57065 87630 79599668
Product solubility abnormal 14.74 11.54 9 57081 963 79686335
Myopathy 14.71 11.54 40 57050 20523 79666775
Hepatic enzyme increased 14.65 11.54 74 57016 182536 79504762
Hypervolaemia 14.62 11.54 65 57025 42625 79644673
Oedema 14.49 11.54 140 56950 119440 79567858
Carotid artery stenosis 14.49 11.54 24 57066 8734 79678564
Lung disorder 14.48 11.54 22 57068 80535 79606763
Aortic stenosis 14.41 11.54 22 57068 7473 79679825
Multiple injuries 14.37 11.54 15 57075 3480 79683818
Psoriatic arthropathy 14.31 11.54 21 57069 77978 79609320
Full blood count decreased 14.28 11.54 47 57043 26772 79660526
Hip arthroplasty 14.18 11.54 4 57086 35752 79651546
Autoimmune myositis 14.14 11.54 6 57084 297 79687001
Glucose urine present 14.12 11.54 11 57079 1745 79685553
High density lipoprotein decreased 14.04 11.54 17 57073 4638 79682660
Product physical issue 13.80 11.54 16 57074 4169 79683129
Nasopharyngitis 13.70 11.54 116 56974 253765 79433533
Alanine aminotransferase increased 13.55 11.54 65 57025 162505 79524793
Circulatory collapse 13.55 11.54 5 57085 37663 79649635
Hypoglycaemic seizure 13.45 11.54 8 57082 816 79686482
Fall 13.44 11.54 450 56640 487179 79200119
Hepatocellular injury 13.10 11.54 9 57081 47584 79639714
Tricuspid valve incompetence 12.78 11.54 37 57053 19675 79667623
Electrocardiogram ST-T change 12.76 11.54 10 57080 1599 79685699
Human anaplasmosis 12.76 11.54 4 57086 82 79687216
Osteoporosis 12.68 11.54 12 57078 54100 79633198
Sinusitis 12.60 11.54 85 57005 195416 79491882
Anaphylactic shock 12.58 11.54 5 57085 35991 79651307
Expiratory reserve volume decreased 12.45 11.54 4 57086 89 79687209
Right ventricular failure 12.35 11.54 41 57049 23456 79663842
Fluid retention 12.35 11.54 89 57001 69720 79617578
Haemorrhage intracranial 12.29 11.54 44 57046 26149 79661149
Neutrophil count decreased 12.26 11.54 31 57059 93928 79593370
Angina pectoris 12.25 11.54 71 57019 51661 79635637
Neurotoxicity 12.24 11.54 4 57086 32514 79654784
Eczema 12.22 11.54 7 57083 40811 79646487
Knee arthroplasty 12.14 11.54 8 57082 43240 79644058
Incorrect route of product administration 11.96 11.54 5 57085 34924 79652374
Laryngeal pain 11.83 11.54 18 57072 6096 79681202
Electrocardiogram QT prolonged 11.66 11.54 30 57060 90356 79596942

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BB07 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Sulfonylureas
FDA CS M0020795 Sulfonylurea Compounds
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:77194 ATP:pantothenate 4-phosphotransferase inhibitor
CHEBI has role CHEBI:90415 insulin secretagogues
MeSH PA D007004 Hypoglycemic Agents
FDA EPC N0000175608 Sulfonylurea

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Alcoholism contraindication 7200002
Asthenia contraindication 13791008
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Infectious disease contraindication 40733004
Hepatic porphyria contraindication 55056006 DOID:3133
Ketoacidosis contraindication 56051008
Metabolic acidosis contraindication 59455009
Hemolytic anemia contraindication 61261009 DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia contraindication 62403005
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Cobalamin deficiency contraindication 190634004
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Severe diarrhea contraindication 409587002
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Prolonged-Severe Nausea and Vomiting contraindication
Radiography with IV Iodinated Contrast Agent contraindication
Severe Hypoxemia contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.31 acidic
pKa2 11.71 acidic
pKa3 12.9 acidic
pKa4 3.19 Basic
pKa5 0.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sulfonylurea receptor 1, Kir6.2 Ion channel BLOCKER Kd 9.10 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
4018508 VUID
N0000146830 NUI
D00335 KEGG_DRUG
4018508 VANDF
C0017642 UMLSCUI
CHEBI:5384 CHEBI
CHEMBL1073 ChEMBL_ID
D005913 MESH_DESCRIPTOR_UI
DB01067 DRUGBANK_ID
6821 IUPHAR_LIGAND_ID
3090 INN_ID
X7WDT95N5C UNII
3478 PUBCHEM_CID
151822 RXNORM
4783 MMSL
574 MMSL
595 MMSL
d00246 MMSL
000913 NDDF
26124005 SNOMEDCT_US
387143009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0170 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 27 sections
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0170 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 27 sections
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0174 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 27 sections
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0174 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 27 sections
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0178 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 27 sections
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0178 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7455 TABLET, FILM COATED 2.50 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7456 TABLET, FILM COATED 2.50 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7457 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0378-1105 TABLET 5 mg ORAL ANDA 25 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0378-1105 TABLET 5 mg ORAL ANDA 25 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0378-1110 TABLET 10 mg ORAL ANDA 25 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0378-1110 TABLET 10 mg ORAL ANDA 25 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0591-0460 TABLET 5 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0591-0460 TABLET 5 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0591-0461 TABLET 10 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0591-0461 TABLET 10 mg ORAL ANDA 13 sections
GlipizideER HUMAN PRESCRIPTION DRUG LABEL 1 0591-0844 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL ANDA 26 sections
GlipizideER HUMAN PRESCRIPTION DRUG LABEL 1 0591-0845 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
GlipizideER HUMAN PRESCRIPTION DRUG LABEL 1 0591-0900 TABLET, FILM COATED, EXTENDED RELEASE 2.50 mg ORAL ANDA 26 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-7968 TABLET 5 mg ORAL ANDA 20 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-7969 TABLET 10 mg ORAL ANDA 20 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8407 TABLET 5 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8407 TABLET 5 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8407 TABLET 5 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8408 TABLET 10 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8408 TABLET 10 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8408 TABLET 10 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0904-6637 TABLET 5 mg ORAL ANDA 20 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 10370-745 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL ANDA 25 sections